🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

My most important CAC paper to date just hit: healio.com/news/cardiolog… CAC is SECONDARY RISK EQUIVALENT AT score >300 (same cohort, not comparing clinical trial patients to observational studies) Khurram Nasir Ron Blankstein Erin D. Michos, M.D. Roger Blumenthal

When #DOACs are ✅,📛, or ❓for Tx JACC Journals. Proud of 🌠post-docs Antoine Bejjani, MD & C. Dini Khairani, MD, MMSc. We discuss where there is evidence of efficacy/safety, where there may be harm (safety or efficacy), and uncertainties Brigham and Women’s Research ... 🧵 👇 jacc.org/doi/10.1016/j.…

🔥Hot off the press🔥 Extremely excited to share our most recent manuscript "Impact of untreated chronic obstructive coronary artery disease and outcomes after TAVR" published in the prestigious European Heart Journal 👇 academic.oup.com/eurheartj/adva…

A tweetorial 🧵 about the STOP-CAD and how to interpret these findings. Please make sure to read the full manuscript below. 👇 🛑CAD ahajournals.org/doi/abs/10.116…

Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial: Circulation 🥸Let's summarize - good morning 👇👇👇

Repost if you agree (and plz comment): The time is NOW for vascular medicine ⁦Society for Vascular Medicine | SVM⁩ ⁦Josh Beckman⁩ ⁦Raghu Kolluri⁩ ⁦herbaronowMD⁩ ⁦Geno Merli MD⁩ ⁦Ido Weinberg, MD⁩ Bruce Gray journals.sagepub.com/doi/10.1177/13…

🌟HYPERTENSION - Diet, lifestyle changes & Pharmacotherapy From : 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension ejinme.com/article/S0953-…

🌟DOAC : When Not to use? From : When Direct Oral Anticoagulants Should Not Be Standard Treatment, JACC State-of-the-Art Review jacc.org/doi/10.1016/j.…

They say "The joy of the task is its reward" but I must admit it is nice to see the book in its print version. This book is a must for anyone preparing for #CCeEXAM #NBE #POCUS boards. Congrats to Editorial team Roshni Sreedharan MD, FASA, FCCM Dr. Sandeep Khanna, Ajit Moghekar and Patrick Collier

Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function JACC Journals jacc.org/doi/10.1016/j.…

🫀Tackling worsening #HFrEF requires a paradigm shift! 💊Rapid initiation of quadruple therapy is vital 🩸Quintuple therapy w/vericiguat & IV Iron can reduce clinical risk and improve pt outcomes jacc.org/doi/epdf/10.10… JACC Journals Srihari S. Naidu, MD Richard Ferraro Dr. Deepak L. Bhatt

Original Article: Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation (AZALEA–TIMI 71 trial) nej.md/3PJcknN Science behind the Study: Uncoupling Thrombosis and Hemostasis by Inhibiting Factor XI nej.md/3Eg76gw #Cardiology

“…individuals with CAC=0 and thoracic aortic calcium [TAC] ≥500 experienced CVD events approaching 20 per 1,000 person years.”

#ACC25 #STRIDE examined Semaglutide in PAD #LBCT 👟function impairment is common in PAD with limited Tx 👟93% completed trial, 1/3 women,~ BMI 28, functionally limited (0.1/mile) 👟Sema 💉🆚UC in T2DM+symptoms PAD: walking distance ⤴️ by 13% out to 1 year🤯💥

Rivawar trial: Warfarina vs rixarobaxan en pacientes con trombo intraventricular post infarto.#ACC25 ➡️Hipótesis: no inferioridad en términos de resolución de trombo a las 12 semanas ➡️261 pacientes Similar resolución de trombo entre ambos, sin diferencias en seguridad

BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

One of the most important trials at American College of Cardiology #ACC25 ! Compared fluid restriction to liberal approach in #HeartFailure. Why? This affects individuals w/HF EVERY DAY! ✨No benefit of Fluid Restriction ✨No HARM for liberal fluid intake ✨Improved QOL in liberal fluid intake

In this #JACCINT pooled analysis of pts w/ left main #SCAD, death occurred in 9%, recurrent MI in 13%, urgent #revascularization in 21%, & #LVAD/heart transplant in 4% at 120 days. Early revascularization significantly reduced these risks! jacc.org/doi/10.1016/j.… #HeartTx #cvMI

#Spironolactone vs #Amiloride for Resistant Hypertension A Randomized Clinical Trial N = 118 (1:1 randomization) 📍 12-week home #SBP ↓:  • Amiloride: −13.6 mm Hg  • Spironolactone: −14.7 mm Hg 📍 Between-group difference: −0.68 mm Hg (90% CI −3.50 to 2.14) ✅

Reevaluating Beta-Blocker Recommendations Post-Myocardial Infarction: Perspective on the 2025 Guideline Update: JACC Journals 🥸Commentary on the guidelines - early beta blocker use post MI - 😱Michael Nanna wrote extensively on this in older pts. 🥸Take a look 👇👇👇